Nowadays many authors suggest the use ofintravitreal triamcinolone acetonide (TA) for the treatment of vitreoretinal diseases, although it can be associated with a high risk of local toxicity. In order to develop a safer injection for clinical use, the purpose of our study is to evaluate the in situ safety of two different triamcinolone preparations, a commercially available TA and a micronized triamcinolone. The experiments were performed on 18 adult male age-matched New Zealand rabbits. The clinical examination included funduscopy with an indirect ophthalmoscope and intraocular pressure (lOP) measurement. At the end of the clinical observations, the animals were sacrified and the eyes enucleated and processed for the morphological evaluation. In our study the main side effect observed was the lOP elevation in the group injected with triamcinolone acetonide. In addition, in the TA-injected group, one eye was enucleated following an endophthalmitis. Our study highlights that doses as low as 4 mg of triamcinolone acetonide injected into the rabbit vitreous may have a local toxic effect in terms of lOP elevation, endophthalmitis occurrence and changes in the retinal morphology. In contrast, the micronized triamcinolone injection shows a less toxic effect in situ, thus suggesting the alternative use of this more reliable preparation which seems to be safer for a clinical use.
Intraocularneovascularization, often accompanied and stimulated by intraocular inflammation, has remained an important problem in clinical ophthalmology. Moreover, defects in the blood-retina barrier due to capillary leakage, with accumulation offluid in the intraretinal and subretinal spaces of the macula, are other major causes of impaired vision. The reasons for such conditions are various and include diabetic retinopathy, retinal vein occlusions and uveitis, to mention only a few.Corticosteroids are known to reduce intraocular inflammation and tighten the capillary walls, and, depending on the concentration, to suppress cell proliferation. For these reasons steroids have been widely used in the treatment ofmany ocular diseases, applied topically as drops, given sistemically or injected into the subconjunctival or sub-Tenon space. Often, however, the intraocular concentration of corticosteroids is too low or the systemic side effects are too pronounced to allow an extended treatment.In order to overcome these limitations, Machemer et al. have suggested the intravitreal application of a crystalline form of steroid that provides intraocularly available drug for a considerably longer period (l). In particular, the intravitreal injection of triamcinolone acetonide . (TA) (9a-fluoro-16a-hydroxyprednisolone) was first proposed in an